Gene H. Kim
Concepts (707)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 61 | 2021 | 686 | 6.520 |
Why?
| Heart Failure | 65 | 2021 | 1075 | 5.870 |
Why?
| Ventricular Function, Left | 21 | 2020 | 559 | 2.310 |
Why?
| Hemodynamics | 23 | 2020 | 677 | 2.270 |
Why?
| Heart Ventricles | 19 | 2021 | 724 | 2.160 |
Why?
| MicroRNAs | 7 | 2017 | 500 | 2.070 |
Why?
| Heart Transplantation | 12 | 2021 | 649 | 1.620 |
Why?
| Arrhythmias, Cardiac | 5 | 2017 | 177 | 1.540 |
Why?
| Pulmonary Wedge Pressure | 12 | 2021 | 107 | 1.370 |
Why?
| Middle Aged | 90 | 2021 | 23948 | 1.240 |
Why?
| Humans | 144 | 2021 | 79512 | 1.160 |
Why?
| Aortic Valve Insufficiency | 7 | 2020 | 120 | 1.160 |
Why?
| Myocardium | 6 | 2017 | 520 | 1.160 |
Why?
| Male | 105 | 2021 | 39419 | 1.100 |
Why?
| Cardiomyopathies | 6 | 2020 | 211 | 1.100 |
Why?
| Female | 100 | 2021 | 42244 | 1.070 |
Why?
| Prosthesis Implantation | 7 | 2020 | 121 | 1.060 |
Why?
| Skin Neoplasms | 6 | 2020 | 510 | 1.040 |
Why?
| Cornea | 2 | 2014 | 65 | 1.010 |
Why?
| Ventricular Remodeling | 3 | 2021 | 89 | 0.950 |
Why?
| Epigenesis, Genetic | 3 | 2017 | 429 | 0.930 |
Why?
| Myocytes, Cardiac | 6 | 2016 | 251 | 0.910 |
Why?
| Echocardiography | 16 | 2020 | 858 | 0.880 |
Why?
| Skin | 6 | 2020 | 538 | 0.880 |
Why?
| S100 Proteins | 5 | 2013 | 49 | 0.860 |
Why?
| Gene Expression Regulation | 9 | 2017 | 1880 | 0.830 |
Why?
| Folliculitis | 1 | 2020 | 2 | 0.810 |
Why?
| Mesotherapy | 1 | 2020 | 2 | 0.810 |
Why?
| Foot Diseases | 1 | 2019 | 12 | 0.800 |
Why?
| Echocardiography, Doppler | 8 | 2020 | 185 | 0.790 |
Why?
| Foot | 1 | 2019 | 52 | 0.780 |
Why?
| Hemangioma | 1 | 2019 | 55 | 0.780 |
Why?
| Signal Transduction | 9 | 2020 | 3144 | 0.750 |
Why?
| Aged | 55 | 2021 | 17394 | 0.750 |
Why?
| Gap Junctions | 2 | 2017 | 141 | 0.740 |
Why?
| Melanoma | 4 | 2020 | 426 | 0.720 |
Why?
| Immunoglobulin G | 4 | 2021 | 442 | 0.710 |
Why?
| Treatment Outcome | 34 | 2021 | 7469 | 0.690 |
Why?
| Retrospective Studies | 33 | 2020 | 7386 | 0.680 |
Why?
| Disease Models, Animal | 9 | 2019 | 2173 | 0.680 |
Why?
| Cosmetic Techniques | 2 | 2015 | 39 | 0.680 |
Why?
| Cardiology | 1 | 2019 | 118 | 0.680 |
Why?
| Desmosomes | 1 | 2017 | 10 | 0.670 |
Why?
| Biopsy | 5 | 2019 | 1117 | 0.660 |
Why?
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 8 | 0.660 |
Why?
| Adult | 44 | 2021 | 24525 | 0.650 |
Why?
| Heart Atria | 2 | 2019 | 231 | 0.640 |
Why?
| Cardiovascular Diseases | 2 | 2014 | 767 | 0.630 |
Why?
| Leg Dermatoses | 1 | 2016 | 7 | 0.630 |
Why?
| Cryptococcosis | 1 | 2016 | 11 | 0.630 |
Why?
| Intra-Aortic Balloon Pumping | 4 | 2020 | 76 | 0.620 |
Why?
| Cellulitis | 1 | 2016 | 19 | 0.620 |
Why?
| Immunocompromised Host | 2 | 2020 | 134 | 0.620 |
Why?
| Fungemia | 1 | 2016 | 15 | 0.620 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2016 | 33 | 0.620 |
Why?
| Regeneration | 1 | 2017 | 139 | 0.610 |
Why?
| Prospective Studies | 25 | 2021 | 3870 | 0.610 |
Why?
| Hemorrhage | 4 | 2018 | 236 | 0.600 |
Why?
| Methanobrevibacter | 2 | 2013 | 2 | 0.600 |
Why?
| Acupuncture Therapy | 1 | 2015 | 10 | 0.580 |
Why?
| Heart Conduction System | 2 | 2012 | 104 | 0.580 |
Why?
| Thrombosis | 5 | 2020 | 265 | 0.570 |
Why?
| Medical Oncology | 1 | 2019 | 323 | 0.570 |
Why?
| Sclerosis | 1 | 2015 | 28 | 0.570 |
Why?
| Cell Nucleus | 2 | 2017 | 571 | 0.570 |
Why?
| Leg Ulcer | 1 | 2014 | 7 | 0.560 |
Why?
| Immunosuppressive Agents | 3 | 2020 | 978 | 0.560 |
Why?
| Irritable Bowel Syndrome | 2 | 2012 | 37 | 0.560 |
Why?
| Tetracaine | 1 | 2014 | 1 | 0.560 |
Why?
| Prostheses and Implants | 2 | 2018 | 127 | 0.560 |
Why?
| Amnion | 1 | 2014 | 13 | 0.560 |
Why?
| Eye Pain | 1 | 2014 | 4 | 0.560 |
Why?
| Animals | 38 | 2020 | 25594 | 0.560 |
Why?
| Embolism | 1 | 2014 | 26 | 0.550 |
Why?
| Coated Materials, Biocompatible | 1 | 2014 | 29 | 0.550 |
Why?
| Conjunctiva | 1 | 2014 | 20 | 0.550 |
Why?
| Granuloma | 1 | 2015 | 62 | 0.550 |
Why?
| Stevens-Johnson Syndrome | 1 | 2014 | 21 | 0.550 |
Why?
| Eye Injuries | 1 | 2014 | 14 | 0.550 |
Why?
| Keratomileusis, Laser In Situ | 1 | 2014 | 2 | 0.540 |
Why?
| Lasers, Excimer | 1 | 2014 | 4 | 0.540 |
Why?
| Photorefractive Keratectomy | 1 | 2014 | 4 | 0.540 |
Why?
| Myopia | 1 | 2014 | 10 | 0.530 |
Why?
| Membrane Glycoproteins | 1 | 2017 | 419 | 0.530 |
Why?
| Foreign Bodies | 1 | 2014 | 54 | 0.530 |
Why?
| Face | 1 | 2015 | 120 | 0.530 |
Why?
| Ventricular Dysfunction, Right | 3 | 2020 | 126 | 0.530 |
Why?
| Prednisone | 3 | 2020 | 252 | 0.520 |
Why?
| Trigeminal Nerve | 1 | 2013 | 17 | 0.520 |
Why?
| Cardiomegaly | 6 | 2016 | 110 | 0.520 |
Why?
| Anesthetics, Local | 1 | 2014 | 79 | 0.520 |
Why?
| Suture Techniques | 1 | 2014 | 126 | 0.510 |
Why?
| Connexin 43 | 1 | 2014 | 94 | 0.510 |
Why?
| Thromboembolism | 3 | 2018 | 117 | 0.510 |
Why?
| Nerve Fibers | 1 | 2013 | 45 | 0.500 |
Why?
| Panniculitis | 1 | 2013 | 7 | 0.500 |
Why?
| Device Removal | 3 | 2020 | 154 | 0.500 |
Why?
| Lactoglobulins | 1 | 2012 | 7 | 0.490 |
Why?
| Fox-Fordyce Disease | 1 | 2012 | 2 | 0.490 |
Why?
| Xanthomatosis | 1 | 2012 | 8 | 0.490 |
Why?
| Heart | 4 | 2019 | 498 | 0.490 |
Why?
| Follow-Up Studies | 15 | 2021 | 3553 | 0.490 |
Why?
| Hypertrichosis | 1 | 2012 | 4 | 0.490 |
Why?
| Neurocytoma | 1 | 2012 | 3 | 0.490 |
Why?
| Cardiac Output | 5 | 2020 | 144 | 0.480 |
Why?
| Facial Neoplasms | 1 | 2012 | 26 | 0.480 |
Why?
| Methane | 1 | 2012 | 10 | 0.470 |
Why?
| Mice | 24 | 2020 | 10710 | 0.460 |
Why?
| Oxidation-Reduction | 1 | 2013 | 356 | 0.460 |
Why?
| Ultrasonography, Prenatal | 1 | 2013 | 151 | 0.450 |
Why?
| Constipation | 1 | 2012 | 57 | 0.450 |
Why?
| Mice, Transgenic | 13 | 2019 | 1509 | 0.450 |
Why?
| Histiocytosis, Non-Langerhans-Cell | 1 | 2011 | 3 | 0.440 |
Why?
| Postoperative Complications | 9 | 2020 | 2067 | 0.440 |
Why?
| Facial Dermatoses | 1 | 2011 | 11 | 0.440 |
Why?
| Indoles | 1 | 2013 | 316 | 0.430 |
Why?
| Sulfonamides | 1 | 2013 | 295 | 0.420 |
Why?
| Hypertension, Pulmonary | 4 | 2020 | 319 | 0.420 |
Why?
| Diagnosis, Differential | 6 | 2019 | 1490 | 0.420 |
Why?
| Atrial Fibrillation | 4 | 2019 | 238 | 0.410 |
Why?
| Sirtuin 3 | 4 | 2016 | 30 | 0.410 |
Why?
| Histiocytosis, Sinus | 2 | 2020 | 14 | 0.400 |
Why?
| Lymphedema | 3 | 2020 | 72 | 0.400 |
Why?
| Recovery of Function | 4 | 2019 | 249 | 0.390 |
Why?
| Kidney Transplantation | 3 | 2021 | 792 | 0.390 |
Why?
| Aortic Valve | 4 | 2020 | 193 | 0.380 |
Why?
| Echocardiography, Three-Dimensional | 4 | 2021 | 497 | 0.370 |
Why?
| Methotrexate | 2 | 2020 | 247 | 0.370 |
Why?
| Anti-Bacterial Agents | 3 | 2020 | 700 | 0.370 |
Why?
| Tricuspid Valve | 2 | 2020 | 87 | 0.370 |
Why?
| Heart Defects, Congenital | 3 | 2021 | 336 | 0.370 |
Why?
| Liver Transplantation | 4 | 2021 | 1238 | 0.370 |
Why?
| Transforming Growth Factor beta1 | 1 | 2009 | 83 | 0.370 |
Why?
| Autoimmune Diseases | 3 | 2021 | 232 | 0.370 |
Why?
| Pulmonary Artery | 3 | 2021 | 283 | 0.370 |
Why?
| Counterpulsation | 2 | 2018 | 21 | 0.350 |
Why?
| Tricuspid Valve Insufficiency | 2 | 2020 | 97 | 0.350 |
Why?
| Cardiotonic Agents | 3 | 2019 | 81 | 0.350 |
Why?
| Heart Valve Prosthesis Implantation | 2 | 2020 | 148 | 0.350 |
Why?
| Pacemaker, Artificial | 2 | 2020 | 83 | 0.350 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 123 | 0.350 |
Why?
| Lymph Node Excision | 2 | 2019 | 197 | 0.340 |
Why?
| Coronary Artery Bypass | 3 | 2020 | 201 | 0.340 |
Why?
| Gastrointestinal Hemorrhage | 3 | 2020 | 215 | 0.340 |
Why?
| Radiotherapy | 2 | 2019 | 324 | 0.330 |
Why?
| Photosensitivity Disorders | 1 | 2007 | 15 | 0.330 |
Why?
| Lichen Planus | 1 | 2007 | 9 | 0.330 |
Why?
| Protein Biosynthesis | 1 | 2009 | 369 | 0.320 |
Why?
| Graft Rejection | 4 | 2021 | 1046 | 0.310 |
Why?
| Muscle, Smooth, Vascular | 4 | 2013 | 238 | 0.310 |
Why?
| Energy Metabolism | 2 | 2019 | 254 | 0.310 |
Why?
| Psoriasis | 1 | 2009 | 223 | 0.300 |
Why?
| Wound Healing | 2 | 2020 | 334 | 0.300 |
Why?
| Leiomyomatosis | 1 | 2005 | 12 | 0.300 |
Why?
| Transcription Factors | 2 | 2014 | 1464 | 0.300 |
Why?
| Ventricular Function, Right | 4 | 2020 | 133 | 0.290 |
Why?
| Time Factors | 12 | 2021 | 5143 | 0.290 |
Why?
| Oxidative Stress | 4 | 2019 | 401 | 0.290 |
Why?
| Nails, Malformed | 1 | 2004 | 3 | 0.280 |
Why?
| Urticaria | 1 | 2004 | 10 | 0.280 |
Why?
| Mitochondria | 3 | 2019 | 518 | 0.280 |
Why?
| Hair | 1 | 2004 | 54 | 0.270 |
Why?
| Craniofacial Abnormalities | 1 | 2004 | 35 | 0.270 |
Why?
| Cold Temperature | 1 | 2004 | 153 | 0.270 |
Why?
| DNA-Binding Proteins | 2 | 2012 | 1181 | 0.260 |
Why?
| Patient Readmission | 4 | 2020 | 287 | 0.260 |
Why?
| Osteopoikilosis | 1 | 2003 | 1 | 0.250 |
Why?
| Skin Diseases, Genetic | 1 | 2003 | 3 | 0.250 |
Why?
| Visual Acuity | 2 | 2014 | 185 | 0.250 |
Why?
| Sirtuins | 3 | 2016 | 45 | 0.250 |
Why?
| Central Venous Pressure | 2 | 2020 | 26 | 0.250 |
Why?
| Anticoagulants | 4 | 2019 | 380 | 0.240 |
Why?
| Abnormalities, Multiple | 1 | 2004 | 230 | 0.240 |
Why?
| Uterine Neoplasms | 1 | 2005 | 186 | 0.240 |
Why?
| T-Lymphocytes | 1 | 2009 | 1193 | 0.230 |
Why?
| Survival Rate | 7 | 2021 | 1809 | 0.230 |
Why?
| Proportional Hazards Models | 6 | 2020 | 823 | 0.230 |
Why?
| Complement C3d | 1 | 2021 | 6 | 0.230 |
Why?
| 3' Untranslated Regions | 2 | 2014 | 90 | 0.230 |
Why?
| NIH 3T3 Cells | 2 | 2014 | 104 | 0.230 |
Why?
| Skin Diseases, Vesiculobullous | 1 | 2021 | 18 | 0.220 |
Why?
| Aortic Aneurysm | 2 | 2014 | 78 | 0.220 |
Why?
| Stroke Volume | 3 | 2019 | 407 | 0.220 |
Why?
| Complement C4b | 1 | 2021 | 34 | 0.220 |
Why?
| Blood Flow Velocity | 2 | 2019 | 196 | 0.220 |
Why?
| Bone and Bones | 1 | 2003 | 254 | 0.220 |
Why?
| Kidney Failure, Chronic | 2 | 2020 | 500 | 0.220 |
Why?
| Apolipoproteins E | 2 | 2013 | 115 | 0.220 |
Why?
| Risk Factors | 8 | 2020 | 5099 | 0.210 |
Why?
| Cohort Studies | 9 | 2020 | 2561 | 0.210 |
Why?
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 11 | 0.210 |
Why?
| Glomus Tumor | 1 | 2020 | 6 | 0.210 |
Why?
| Atherosclerosis | 2 | 2014 | 219 | 0.210 |
Why?
| Penicillin G Benzathine | 1 | 2020 | 5 | 0.210 |
Why?
| Agammaglobulinemia | 1 | 2020 | 19 | 0.210 |
Why?
| Sulfadiazine | 1 | 2020 | 24 | 0.210 |
Why?
| Treponema pallidum | 1 | 2020 | 8 | 0.210 |
Why?
| Trimethoprim | 1 | 2020 | 16 | 0.210 |
Why?
| Epidermolysis Bullosa, Junctional | 1 | 2020 | 1 | 0.200 |
Why?
| Ambulatory Care | 2 | 2018 | 168 | 0.200 |
Why?
| Gentamicins | 1 | 2020 | 29 | 0.200 |
Why?
| Risk Assessment | 5 | 2020 | 2158 | 0.200 |
Why?
| HIV Seropositivity | 1 | 2020 | 48 | 0.200 |
Why?
| Cause of Death | 2 | 2018 | 269 | 0.200 |
Why?
| Primary Graft Dysfunction | 1 | 2020 | 28 | 0.200 |
Why?
| Poroma | 1 | 2019 | 1 | 0.200 |
Why?
| Syphilis | 1 | 2020 | 24 | 0.200 |
Why?
| Codon, Nonsense | 1 | 2020 | 38 | 0.200 |
Why?
| Sweat Gland Neoplasms | 1 | 2019 | 6 | 0.200 |
Why?
| Mathematical Concepts | 1 | 2020 | 17 | 0.200 |
Why?
| Fontan Procedure | 1 | 2020 | 51 | 0.200 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2020 | 80 | 0.200 |
Why?
| Porokeratosis | 1 | 2019 | 3 | 0.200 |
Why?
| Tachycardia, Ventricular | 1 | 2020 | 102 | 0.200 |
Why?
| Ambulatory Surgical Procedures | 1 | 2020 | 73 | 0.190 |
Why?
| Severity of Illness Index | 7 | 2020 | 1686 | 0.190 |
Why?
| Intraoperative Care | 1 | 2020 | 80 | 0.190 |
Why?
| Vascular Stiffness | 1 | 2019 | 26 | 0.190 |
Why?
| Electric Impedance | 1 | 2020 | 100 | 0.190 |
Why?
| Syndrome | 3 | 2005 | 419 | 0.190 |
Why?
| Hair Follicle | 1 | 2019 | 26 | 0.190 |
Why?
| Cartilage | 2 | 2018 | 111 | 0.190 |
Why?
| Cheek | 2 | 2011 | 20 | 0.190 |
Why?
| Protease Inhibitors | 1 | 2019 | 71 | 0.190 |
Why?
| Peptide Fragments | 1 | 2021 | 455 | 0.190 |
Why?
| Vasodilation | 1 | 2019 | 98 | 0.190 |
Why?
| Tetrazoles | 1 | 2019 | 49 | 0.190 |
Why?
| Neoplasms, Second Primary | 2 | 2020 | 242 | 0.190 |
Why?
| Cell Adhesion Molecules | 1 | 2020 | 160 | 0.190 |
Why?
| Mice, Knockout | 8 | 2019 | 1904 | 0.190 |
Why?
| Adrenergic beta-Antagonists | 1 | 2020 | 158 | 0.190 |
Why?
| Sternotomy | 1 | 2019 | 17 | 0.190 |
Why?
| Biphenyl Compounds | 2 | 2019 | 68 | 0.190 |
Why?
| Myocarditis | 1 | 2019 | 47 | 0.190 |
Why?
| Calcinosis | 2 | 2011 | 232 | 0.190 |
Why?
| Multiple Organ Failure | 1 | 2019 | 41 | 0.190 |
Why?
| Remote Sensing Technology | 1 | 2018 | 5 | 0.190 |
Why?
| Assisted Circulation | 1 | 2018 | 14 | 0.190 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 95 | 0.180 |
Why?
| Heart Function Tests | 1 | 2018 | 28 | 0.180 |
Why?
| Lunate Bone | 1 | 2018 | 2 | 0.180 |
Why?
| Thyroid Diseases | 1 | 2019 | 105 | 0.180 |
Why?
| Guided Tissue Regeneration | 1 | 2018 | 7 | 0.180 |
Why?
| Shock, Cardiogenic | 1 | 2019 | 77 | 0.180 |
Why?
| Trapezium Bone | 1 | 2018 | 6 | 0.180 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 248 | 0.180 |
Why?
| Donor Selection | 1 | 2019 | 65 | 0.180 |
Why?
| Carpometacarpal Joints | 1 | 2018 | 12 | 0.180 |
Why?
| Atrial Appendage | 1 | 2018 | 25 | 0.180 |
Why?
| Reperfusion Injury | 1 | 2020 | 133 | 0.180 |
Why?
| Mice, Inbred C57BL | 9 | 2019 | 3052 | 0.180 |
Why?
| Nerve Tissue Proteins | 2 | 2013 | 489 | 0.180 |
Why?
| Subclavian Artery | 2 | 2015 | 39 | 0.180 |
Why?
| Predictive Value of Tests | 6 | 2019 | 1618 | 0.180 |
Why?
| Arthroplasty | 1 | 2018 | 28 | 0.180 |
Why?
| Pemphigoid, Bullous | 2 | 2021 | 12 | 0.180 |
Why?
| Alopecia | 2 | 2019 | 34 | 0.180 |
Why?
| Catheter Ablation | 1 | 2020 | 213 | 0.180 |
Why?
| Natriuretic Peptide, Brain | 1 | 2018 | 54 | 0.180 |
Why?
| Enoxaparin | 1 | 2018 | 23 | 0.180 |
Why?
| Octreotide | 1 | 2018 | 16 | 0.170 |
Why?
| Fatty Acids, Omega-3 | 1 | 2018 | 50 | 0.170 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2019 | 63 | 0.170 |
Why?
| Tattooing | 1 | 2017 | 6 | 0.170 |
Why?
| Erythema Nodosum | 1 | 2017 | 4 | 0.170 |
Why?
| Mitral Valve | 1 | 2020 | 232 | 0.170 |
Why?
| Equipment Failure | 4 | 2020 | 120 | 0.170 |
Why?
| Graphite | 1 | 2017 | 9 | 0.170 |
Why?
| Rats | 8 | 2020 | 3921 | 0.170 |
Why?
| Ubiquitin Thiolesterase | 1 | 2018 | 55 | 0.170 |
Why?
| Testosterone | 1 | 2019 | 265 | 0.170 |
Why?
| Sarcoidosis, Pulmonary | 1 | 2017 | 15 | 0.170 |
Why?
| Nevus, Pigmented | 1 | 2018 | 48 | 0.170 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 158 | 0.170 |
Why?
| Eye Injuries, Penetrating | 1 | 2017 | 5 | 0.170 |
Why?
| Heart Valve Diseases | 1 | 2018 | 97 | 0.170 |
Why?
| Skin Ulcer | 1 | 2017 | 25 | 0.170 |
Why?
| Neoplasms, Multiple Primary | 1 | 2018 | 101 | 0.170 |
Why?
| Rhinoplasty | 1 | 2018 | 31 | 0.170 |
Why?
| Illusions | 1 | 2017 | 11 | 0.170 |
Why?
| Thermodilution | 1 | 2017 | 20 | 0.170 |
Why?
| Surgical Flaps | 1 | 2020 | 246 | 0.160 |
Why?
| Desmocollins | 1 | 2017 | 3 | 0.160 |
Why?
| Secondary Prevention | 1 | 2018 | 161 | 0.160 |
Why?
| Myocardial Ischemia | 2 | 2017 | 150 | 0.160 |
Why?
| Atrial Flutter | 1 | 2017 | 33 | 0.160 |
Why?
| Insulin Resistance | 1 | 2019 | 366 | 0.160 |
Why?
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 20 | 0.160 |
Why?
| Fibronectins | 1 | 2017 | 91 | 0.160 |
Why?
| Cryptococcus neoformans | 1 | 2016 | 9 | 0.160 |
Why?
| Fluconazole | 1 | 2016 | 10 | 0.160 |
Why?
| Flucytosine | 1 | 2016 | 11 | 0.160 |
Why?
| Amphotericin B | 1 | 2016 | 34 | 0.160 |
Why?
| Hydrogen Sulfide | 1 | 2017 | 45 | 0.160 |
Why?
| Carbon Monoxide | 1 | 2017 | 94 | 0.160 |
Why?
| Angiopoietin-2 | 1 | 2016 | 18 | 0.150 |
Why?
| Prosthesis Design | 4 | 2019 | 268 | 0.150 |
Why?
| Defibrillators, Implantable | 1 | 2018 | 122 | 0.150 |
Why?
| Tumor Suppressor Proteins | 1 | 2018 | 273 | 0.150 |
Why?
| Coloring Agents | 2 | 2012 | 65 | 0.150 |
Why?
| Sleep Apnea Syndromes | 1 | 2017 | 97 | 0.150 |
Why?
| Radiation Injuries | 1 | 2017 | 158 | 0.150 |
Why?
| Tissue and Organ Procurement | 1 | 2019 | 265 | 0.150 |
Why?
| Reproducibility of Results | 4 | 2018 | 2570 | 0.150 |
Why?
| Mitochondria, Heart | 1 | 2016 | 45 | 0.150 |
Why?
| Lymph Nodes | 1 | 2020 | 507 | 0.150 |
Why?
| Superoxide Dismutase | 3 | 2015 | 173 | 0.150 |
Why?
| Extracellular Matrix | 1 | 2017 | 224 | 0.150 |
Why?
| Antifungal Agents | 1 | 2016 | 110 | 0.150 |
Why?
| Rats, Inbred SHR | 2 | 2017 | 29 | 0.150 |
Why?
| Observer Variation | 2 | 2016 | 589 | 0.150 |
Why?
| Phenotype | 3 | 2017 | 2246 | 0.140 |
Why?
| Lignans | 1 | 2015 | 6 | 0.140 |
Why?
| Cyclosporine | 1 | 2016 | 240 | 0.140 |
Why?
| Incidence | 5 | 2019 | 1528 | 0.140 |
Why?
| Doxorubicin | 1 | 2016 | 277 | 0.140 |
Why?
| Lasers, Gas | 1 | 2014 | 4 | 0.140 |
Why?
| DNA, Mitochondrial | 1 | 2016 | 179 | 0.140 |
Why?
| Combined Modality Therapy | 1 | 2019 | 1602 | 0.140 |
Why?
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2014 | 14 | 0.140 |
Why?
| Cephalosporins | 1 | 2014 | 26 | 0.140 |
Why?
| LIM Domain Proteins | 1 | 2014 | 25 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 283 | 0.140 |
Why?
| Mesenteric Artery, Superior | 1 | 2014 | 18 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2020 | 302 | 0.140 |
Why?
| Sensitivity and Specificity | 4 | 2018 | 1937 | 0.140 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 411 | 0.140 |
Why?
| Toxoplasmosis | 1 | 2015 | 63 | 0.140 |
Why?
| Mitral Valve Insufficiency | 1 | 2016 | 176 | 0.140 |
Why?
| Refraction, Ocular | 1 | 2014 | 9 | 0.130 |
Why?
| Infant | 3 | 2021 | 2924 | 0.130 |
Why?
| Posture | 1 | 2014 | 105 | 0.130 |
Why?
| Melkersson-Rosenthal Syndrome | 1 | 2014 | 1 | 0.130 |
Why?
| Eyelid Diseases | 1 | 2014 | 6 | 0.130 |
Why?
| Immunohistochemistry | 4 | 2021 | 1722 | 0.130 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2014 | 10 | 0.130 |
Why?
| Nails | 1 | 2014 | 7 | 0.130 |
Why?
| Transforming Growth Factor beta | 2 | 2013 | 273 | 0.130 |
Why?
| Transduction, Genetic | 1 | 2014 | 150 | 0.130 |
Why?
| Hospitalization | 1 | 2019 | 748 | 0.130 |
Why?
| Luciferases | 1 | 2014 | 119 | 0.130 |
Why?
| Patient Positioning | 1 | 2014 | 57 | 0.130 |
Why?
| Connective Tissue Diseases | 1 | 2014 | 62 | 0.130 |
Why?
| Exosomes | 1 | 2014 | 45 | 0.130 |
Why?
| Catheterization, Peripheral | 1 | 2014 | 58 | 0.130 |
Why?
| Mutation, Missense | 2 | 2013 | 269 | 0.130 |
Why?
| Myosin Heavy Chains | 1 | 2014 | 86 | 0.130 |
Why?
| Genetic Testing | 1 | 2018 | 487 | 0.130 |
Why?
| Arterial Occlusive Diseases | 1 | 2014 | 97 | 0.130 |
Why?
| Neovascularization, Pathologic | 1 | 2016 | 337 | 0.130 |
Why?
| Electrocardiography | 4 | 2019 | 466 | 0.130 |
Why?
| DNA Damage | 1 | 2016 | 348 | 0.130 |
Why?
| Cells, Cultured | 6 | 2020 | 2787 | 0.130 |
Why?
| Edema | 1 | 2014 | 71 | 0.130 |
Why?
| Gastrointestinal Agents | 2 | 2018 | 174 | 0.130 |
Why?
| Vasculitis | 2 | 2013 | 37 | 0.130 |
Why?
| Frozen Sections | 1 | 2014 | 44 | 0.130 |
Why?
| Genes, Reporter | 1 | 2014 | 258 | 0.130 |
Why?
| Carcinoma, Squamous Cell | 1 | 2020 | 1025 | 0.130 |
Why?
| Neoplasm Metastasis | 2 | 2020 | 1032 | 0.130 |
Why?
| Prognosis | 5 | 2021 | 3522 | 0.130 |
Why?
| Tomography, X-Ray Computed | 3 | 2017 | 2439 | 0.120 |
Why?
| Oxygen Consumption | 1 | 2014 | 234 | 0.120 |
Why?
| Carmine | 1 | 2012 | 1 | 0.120 |
Why?
| Foam Cells | 1 | 2012 | 17 | 0.120 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 8 | 0.120 |
Why?
| Illinois | 3 | 2019 | 446 | 0.120 |
Why?
| Reoperation | 3 | 2020 | 562 | 0.120 |
Why?
| Plaque, Atherosclerotic | 1 | 2013 | 39 | 0.120 |
Why?
| Mucins | 1 | 2012 | 40 | 0.120 |
Why?
| Oncogene Protein v-akt | 1 | 2012 | 22 | 0.120 |
Why?
| Ventricular Dysfunction, Left | 1 | 2015 | 292 | 0.120 |
Why?
| Genetic Vectors | 1 | 2014 | 429 | 0.120 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2012 | 45 | 0.120 |
Why?
| Electrophysiological Phenomena | 1 | 2012 | 47 | 0.120 |
Why?
| Microscopy, Confocal | 1 | 2013 | 269 | 0.120 |
Why?
| Acute Disease | 1 | 2014 | 802 | 0.120 |
Why?
| Physicians | 1 | 2019 | 588 | 0.120 |
Why?
| Models, Cardiovascular | 1 | 2012 | 96 | 0.120 |
Why?
| Lung | 1 | 2018 | 1067 | 0.120 |
Why?
| Breath Tests | 1 | 2012 | 55 | 0.120 |
Why?
| Axilla | 1 | 2012 | 92 | 0.120 |
Why?
| Quinolines | 1 | 2013 | 90 | 0.120 |
Why?
| Staining and Labeling | 1 | 2012 | 163 | 0.120 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 110 | 0.120 |
Why?
| Weight Gain | 1 | 2013 | 125 | 0.120 |
Why?
| RNA, Small Interfering | 1 | 2014 | 537 | 0.120 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 118 | 0.120 |
Why?
| Hydrogen | 1 | 2012 | 49 | 0.120 |
Why?
| Recombinant Fusion Proteins | 1 | 2014 | 555 | 0.110 |
Why?
| Rats, Sprague-Dawley | 4 | 2020 | 1190 | 0.110 |
Why?
| Diabetes Mellitus | 1 | 2019 | 742 | 0.110 |
Why?
| Collagen Type VII | 1 | 2011 | 3 | 0.110 |
Why?
| Epidermolysis Bullosa Acquisita | 1 | 2011 | 2 | 0.110 |
Why?
| Calcium Signaling | 1 | 2012 | 129 | 0.110 |
Why?
| Cell Communication | 1 | 2012 | 187 | 0.110 |
Why?
| Feasibility Studies | 3 | 2018 | 720 | 0.110 |
Why?
| Dermatologic Agents | 1 | 2012 | 69 | 0.110 |
Why?
| Amino Acid Substitution | 1 | 2013 | 341 | 0.110 |
Why?
| Coronary Artery Disease | 1 | 2016 | 323 | 0.110 |
Why?
| RNA, Bacterial | 1 | 2012 | 106 | 0.110 |
Why?
| Rifamycins | 1 | 2011 | 5 | 0.110 |
Why?
| Sodium Channels | 1 | 2012 | 128 | 0.110 |
Why?
| Muscle, Skeletal | 1 | 2014 | 420 | 0.110 |
Why?
| Environment | 1 | 2013 | 212 | 0.110 |
Why?
| RNA, Ribosomal, 16S | 1 | 2012 | 216 | 0.110 |
Why?
| Homeostasis | 1 | 2013 | 387 | 0.110 |
Why?
| DNA, Bacterial | 1 | 2012 | 232 | 0.110 |
Why?
| T-Box Domain Proteins | 1 | 2012 | 97 | 0.110 |
Why?
| Disease Progression | 3 | 2020 | 1424 | 0.110 |
Why?
| Ion Channels | 1 | 2012 | 242 | 0.110 |
Why?
| Kaplan-Meier Estimate | 3 | 2018 | 845 | 0.110 |
Why?
| Intestine, Small | 1 | 2013 | 290 | 0.110 |
Why?
| Histones | 1 | 2013 | 293 | 0.110 |
Why?
| Muscle Contraction | 3 | 2019 | 278 | 0.100 |
Why?
| Child | 3 | 2021 | 6481 | 0.100 |
Why?
| Fibroblasts | 4 | 2016 | 695 | 0.100 |
Why?
| Recurrence | 3 | 2018 | 1105 | 0.100 |
Why?
| Mitochondria, Muscle | 1 | 2010 | 26 | 0.100 |
Why?
| Child, Preschool | 3 | 2020 | 3544 | 0.100 |
Why?
| Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 13 | 0.100 |
Why?
| Feces | 1 | 2012 | 292 | 0.100 |
Why?
| Ergocalciferols | 1 | 2010 | 38 | 0.100 |
Why?
| Autoimmunity | 1 | 2011 | 155 | 0.100 |
Why?
| Neural Crest | 1 | 2010 | 24 | 0.100 |
Why?
| Vascular Diseases | 1 | 2011 | 112 | 0.100 |
Why?
| NAD | 1 | 2009 | 59 | 0.100 |
Why?
| Hypertrophy, Left Ventricular | 1 | 2010 | 68 | 0.100 |
Why?
| Rare Diseases | 2 | 2020 | 55 | 0.100 |
Why?
| Drug Combinations | 2 | 2020 | 223 | 0.100 |
Why?
| Lymphatic System | 2 | 2019 | 51 | 0.100 |
Why?
| AMP-Activated Protein Kinases | 1 | 2009 | 60 | 0.100 |
Why?
| Biopsy, Needle | 2 | 2020 | 233 | 0.090 |
Why?
| Aged, 80 and over | 4 | 2020 | 6195 | 0.090 |
Why?
| Mice, Inbred Strains | 1 | 2009 | 310 | 0.090 |
Why?
| Osteogenesis | 1 | 2010 | 237 | 0.090 |
Why?
| Delayed-Action Preparations | 2 | 2019 | 118 | 0.090 |
Why?
| DNA Methylation | 1 | 2013 | 568 | 0.090 |
Why?
| Forkhead Transcription Factors | 1 | 2009 | 163 | 0.090 |
Why?
| Mitochondrial Proteins | 1 | 2009 | 119 | 0.090 |
Why?
| Cell Proliferation | 2 | 2015 | 1540 | 0.090 |
Why?
| Antineoplastic Agents | 1 | 2019 | 2268 | 0.090 |
Why?
| Tissue Donors | 2 | 2021 | 412 | 0.090 |
Why?
| Cell Differentiation | 2 | 2015 | 1417 | 0.080 |
Why?
| Vitamin D | 1 | 2010 | 252 | 0.080 |
Why?
| Young Adult | 4 | 2021 | 5701 | 0.080 |
Why?
| Blood Pressure | 1 | 2013 | 1141 | 0.080 |
Why?
| Hydroquinones | 1 | 2007 | 8 | 0.080 |
Why?
| Hair Removal | 1 | 2007 | 13 | 0.080 |
Why?
| Forehead | 1 | 2007 | 18 | 0.080 |
Why?
| Exercise Test | 2 | 2019 | 156 | 0.080 |
Why?
| Reactive Oxygen Species | 3 | 2016 | 441 | 0.080 |
Why?
| United States | 4 | 2021 | 6050 | 0.080 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 898 | 0.080 |
Why?
| Radiation-Protective Agents | 1 | 2007 | 96 | 0.080 |
Why?
| Fumarate Hydratase | 1 | 2005 | 6 | 0.080 |
Why?
| Cell Movement | 1 | 2010 | 733 | 0.080 |
Why?
| Reference Values | 2 | 2018 | 653 | 0.080 |
Why?
| Comorbidity | 2 | 2020 | 907 | 0.080 |
Why?
| Pregnancy | 1 | 2013 | 2670 | 0.070 |
Why?
| Ultraviolet Rays | 1 | 2007 | 190 | 0.070 |
Why?
| Academic Medical Centers | 2 | 2018 | 356 | 0.070 |
Why?
| Alopecia Areata | 1 | 2005 | 4 | 0.070 |
Why?
| Survival Analysis | 2 | 2020 | 1519 | 0.070 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 84 | 0.070 |
Why?
| Hydrocortisone | 1 | 2007 | 289 | 0.070 |
Why?
| Patient Selection | 2 | 2020 | 662 | 0.070 |
Why?
| Nuclear Proteins | 1 | 2009 | 679 | 0.070 |
Why?
| Point Mutation | 1 | 2005 | 246 | 0.070 |
Why?
| Ultrasonography | 2 | 2020 | 648 | 0.070 |
Why?
| Acetylcholine | 1 | 2004 | 177 | 0.070 |
Why?
| Random Allocation | 2 | 2018 | 334 | 0.070 |
Why?
| Dacryocystorhinostomy | 1 | 2004 | 4 | 0.070 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 334 | 0.070 |
Why?
| Acetylation | 2 | 2015 | 121 | 0.060 |
Why?
| Treatment Failure | 2 | 2020 | 281 | 0.060 |
Why?
| Collagen | 2 | 2019 | 262 | 0.060 |
Why?
| Age Factors | 2 | 2018 | 1797 | 0.060 |
Why?
| Elastic Tissue | 2 | 2014 | 17 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2014 | 220 | 0.060 |
Why?
| Dermatitis Herpetiformis | 1 | 2021 | 9 | 0.060 |
Why?
| Animals, Newborn | 2 | 2014 | 520 | 0.060 |
Why?
| Pemphigus | 1 | 2021 | 15 | 0.060 |
Why?
| RNA, Messenger | 3 | 2013 | 1920 | 0.060 |
Why?
| Paraffin Embedding | 1 | 2021 | 77 | 0.060 |
Why?
| Immunoglobulin M | 1 | 2021 | 154 | 0.050 |
Why?
| ABO Blood-Group System | 1 | 2021 | 62 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2005 | 677 | 0.050 |
Why?
| Immunoglobulin A | 1 | 2021 | 82 | 0.050 |
Why?
| Myocytes, Smooth Muscle | 2 | 2013 | 131 | 0.050 |
Why?
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
| Pilot Projects | 2 | 2019 | 796 | 0.050 |
Why?
| Bilirubin | 1 | 2021 | 122 | 0.050 |
Why?
| Radiography | 1 | 2003 | 804 | 0.050 |
Why?
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
| Aorta | 2 | 2013 | 291 | 0.050 |
Why?
| Trauma Severity Indices | 1 | 2020 | 40 | 0.050 |
Why?
| Syphilis Serodiagnosis | 1 | 2020 | 5 | 0.050 |
Why?
| Receptors, Immunologic | 2 | 2013 | 134 | 0.050 |
Why?
| Syphilis, Cutaneous | 1 | 2020 | 3 | 0.050 |
Why?
| Immunocompetence | 1 | 2020 | 26 | 0.050 |
Why?
| Mice, Inbred ICR | 1 | 2020 | 68 | 0.050 |
Why?
| California | 1 | 2020 | 136 | 0.050 |
Why?
| Thoracic Surgical Procedures | 1 | 2020 | 42 | 0.050 |
Why?
| Exanthema | 1 | 2020 | 32 | 0.050 |
Why?
| Administration, Cutaneous | 1 | 2020 | 50 | 0.050 |
Why?
| Epigastric Arteries | 1 | 2020 | 9 | 0.050 |
Why?
| Rats, Transgenic | 1 | 2019 | 3 | 0.050 |
Why?
| Hyponatremia | 1 | 2020 | 24 | 0.050 |
Why?
| Euthyroid Sick Syndromes | 1 | 2019 | 10 | 0.050 |
Why?
| Reperfusion | 1 | 2020 | 26 | 0.050 |
Why?
| Neurotransmitter Agents | 1 | 2020 | 101 | 0.050 |
Why?
| Dissection | 1 | 2020 | 42 | 0.050 |
Why?
| Endocrine System Diseases | 1 | 2019 | 23 | 0.050 |
Why?
| Succinate Dehydrogenase | 1 | 2019 | 15 | 0.050 |
Why?
| Sturge-Weber Syndrome | 1 | 2019 | 6 | 0.050 |
Why?
| Neprilysin | 1 | 2019 | 41 | 0.050 |
Why?
| Femoral Artery | 1 | 2020 | 81 | 0.050 |
Why?
| Electron Transport Complex IV | 1 | 2019 | 46 | 0.050 |
Why?
| Patient Care Planning | 1 | 2020 | 80 | 0.050 |
Why?
| Lymphoma, Mantle-Cell | 1 | 2019 | 32 | 0.050 |
Why?
| Fatal Outcome | 1 | 2020 | 284 | 0.050 |
Why?
| Hyperthyroidism | 1 | 2019 | 70 | 0.050 |
Why?
| Materials Testing | 1 | 2019 | 90 | 0.050 |
Why?
| Diabetes Complications | 1 | 2021 | 207 | 0.050 |
Why?
| Metabolic Diseases | 1 | 2019 | 46 | 0.050 |
Why?
| Interdisciplinary Communication | 1 | 2020 | 123 | 0.050 |
Why?
| Hindlimb | 1 | 2019 | 86 | 0.050 |
Why?
| Hyperplasia | 1 | 2019 | 141 | 0.050 |
Why?
| Neck | 1 | 2019 | 90 | 0.050 |
Why?
| Keratinocytes | 1 | 2020 | 134 | 0.050 |
Why?
| Head | 1 | 2019 | 118 | 0.050 |
Why?
| Heparin | 1 | 2019 | 165 | 0.050 |
Why?
| Epidermis | 1 | 2019 | 97 | 0.050 |
Why?
| Systole | 1 | 2019 | 132 | 0.050 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 125 | 0.050 |
Why?
| Patient Compliance | 1 | 2020 | 220 | 0.050 |
Why?
| Administration, Oral | 1 | 2020 | 686 | 0.040 |
Why?
| Thyrotropin | 1 | 2019 | 268 | 0.040 |
Why?
| Organ Size | 1 | 2019 | 353 | 0.040 |
Why?
| Transplantation, Homologous | 1 | 2021 | 972 | 0.040 |
Why?
| Green Fluorescent Proteins | 1 | 2019 | 296 | 0.040 |
Why?
| Mutation | 1 | 2009 | 3745 | 0.040 |
Why?
| Rats, Nude | 1 | 2018 | 22 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2018 | 62 | 0.040 |
Why?
| Coronary Circulation | 1 | 2018 | 129 | 0.040 |
Why?
| Thyroxine | 1 | 2019 | 318 | 0.040 |
Why?
| Ink | 1 | 2017 | 4 | 0.040 |
Why?
| Hypothyroidism | 1 | 2019 | 210 | 0.040 |
Why?
| International Normalized Ratio | 1 | 2018 | 37 | 0.040 |
Why?
| Fascia | 1 | 2018 | 31 | 0.040 |
Why?
| Medical History Taking | 1 | 2018 | 83 | 0.040 |
Why?
| Ischemia | 1 | 2020 | 240 | 0.040 |
Why?
| Registries | 1 | 2021 | 648 | 0.040 |
Why?
| Hospitals, University | 1 | 2018 | 194 | 0.040 |
Why?
| Databases, Factual | 1 | 2021 | 756 | 0.040 |
Why?
| Neutropenia | 1 | 2018 | 210 | 0.040 |
Why?
| Graft Survival | 1 | 2021 | 864 | 0.040 |
Why?
| Administration, Topical | 1 | 2017 | 90 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2021 | 947 | 0.040 |
Why?
| Protein Array Analysis | 1 | 2017 | 50 | 0.040 |
Why?
| Hypoalbuminemia | 1 | 2017 | 6 | 0.040 |
Why?
| Carcinoma, Hepatocellular | 1 | 2001 | 323 | 0.040 |
Why?
| Cell Survival | 1 | 2020 | 952 | 0.040 |
Why?
| Rabbits | 1 | 2018 | 656 | 0.040 |
Why?
| Rats, Inbred WKY | 1 | 2017 | 31 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 902 | 0.040 |
Why?
| Protein Binding | 2 | 2013 | 1447 | 0.040 |
Why?
| Tachycardia | 1 | 2017 | 35 | 0.040 |
Why?
| Heme Oxygenase (Decyclizing) | 1 | 2017 | 40 | 0.040 |
Why?
| Cystathionine gamma-Lyase | 1 | 2017 | 35 | 0.040 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2018 | 113 | 0.040 |
Why?
| Epithelium | 1 | 2018 | 311 | 0.040 |
Why?
| Hospital Mortality | 1 | 2019 | 318 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2018 | 316 | 0.040 |
Why?
| Chi-Square Distribution | 1 | 2017 | 359 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 146 | 0.040 |
Why?
| Equipment Safety | 1 | 2016 | 31 | 0.040 |
Why?
| Risk | 1 | 2018 | 669 | 0.040 |
Why?
| Prevalence | 1 | 2020 | 1163 | 0.040 |
Why?
| Swine | 1 | 2018 | 539 | 0.040 |
Why?
| Thrombin | 1 | 2016 | 61 | 0.040 |
Why?
| Arteriovenous Malformations | 1 | 2016 | 33 | 0.040 |
Why?
| Renal Insufficiency | 1 | 2017 | 105 | 0.040 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 60 | 0.040 |
Why?
| DNA Adducts | 1 | 2016 | 19 | 0.040 |
Why?
| Length of Stay | 1 | 2019 | 647 | 0.040 |
Why?
| DNA Glycosylases | 1 | 2016 | 24 | 0.040 |
Why?
| Deoxyguanosine | 1 | 2016 | 27 | 0.040 |
Why?
| Hydrolysis | 1 | 2016 | 143 | 0.040 |
Why?
| Adolescent | 2 | 2020 | 8657 | 0.040 |
Why?
| Atovaquone | 1 | 2015 | 3 | 0.040 |
Why?
| Liver Neoplasms | 1 | 2001 | 620 | 0.040 |
Why?
| Prosthesis Failure | 1 | 2016 | 112 | 0.040 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 5 | 0.040 |
Why?
| Contrast Media | 1 | 2020 | 1008 | 0.040 |
Why?
| Phenylephrine | 1 | 2015 | 35 | 0.040 |
Why?
| Exercise Tolerance | 1 | 2015 | 47 | 0.040 |
Why?
| Isoproterenol | 1 | 2015 | 57 | 0.040 |
Why?
| Germ-Line Mutation | 1 | 2018 | 294 | 0.040 |
Why?
| Respiration | 1 | 2017 | 238 | 0.040 |
Why?
| Sex Factors | 1 | 2018 | 1021 | 0.040 |
Why?
| Neuromuscular Junction Diseases | 1 | 2014 | 3 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2015 | 73 | 0.040 |
Why?
| Equipment Design | 1 | 2016 | 400 | 0.040 |
Why?
| Chicago | 1 | 2019 | 1327 | 0.040 |
Why?
| Case-Control Studies | 1 | 2019 | 1722 | 0.030 |
Why?
| Cell Death | 1 | 2016 | 253 | 0.030 |
Why?
| Lung Diseases | 1 | 2017 | 252 | 0.030 |
Why?
| Anti-Infective Agents | 1 | 2015 | 82 | 0.030 |
Why?
| Myofibroblasts | 1 | 2015 | 36 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 555 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2017 | 962 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2017 | 1175 | 0.030 |
Why?
| KATP Channels | 1 | 2014 | 19 | 0.030 |
Why?
| Ultrasonography, Doppler | 1 | 2014 | 69 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 28 | 0.030 |
Why?
| Radiography, Abdominal | 1 | 2014 | 68 | 0.030 |
Why?
| Adenosine Triphosphatases | 1 | 2015 | 151 | 0.030 |
Why?
| Carotid Body | 1 | 2017 | 224 | 0.030 |
Why?
| Aortography | 1 | 2013 | 57 | 0.030 |
Why?
| Enzyme Activation | 1 | 2015 | 691 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2018 | 1969 | 0.030 |
Why?
| rho GTP-Binding Proteins | 1 | 2013 | 54 | 0.030 |
Why?
| Fatty Acids | 1 | 2014 | 123 | 0.030 |
Why?
| Endothelial Cells | 1 | 2016 | 385 | 0.030 |
Why?
| Hypotension | 1 | 2013 | 66 | 0.030 |
Why?
| Tetrazolium Salts | 1 | 2012 | 11 | 0.030 |
Why?
| Calgranulin B | 1 | 2013 | 15 | 0.030 |
Why?
| Body Weight | 1 | 2014 | 457 | 0.030 |
Why?
| rhoA GTP-Binding Protein | 1 | 2013 | 84 | 0.030 |
Why?
| NFATC Transcription Factors | 1 | 2012 | 28 | 0.030 |
Why?
| Leucine | 1 | 2012 | 67 | 0.030 |
Why?
| Stroke | 1 | 2020 | 752 | 0.030 |
Why?
| Histone Demethylases | 1 | 2012 | 24 | 0.030 |
Why?
| Zinc | 1 | 2013 | 88 | 0.030 |
Why?
| Quality of Life | 1 | 2020 | 1342 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2012 | 75 | 0.030 |
Why?
| Head and Neck Neoplasms | 1 | 2019 | 997 | 0.030 |
Why?
| Immunoglobulin E | 1 | 2012 | 142 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2013 | 101 | 0.030 |
Why?
| Insulin-Like Growth Factor I | 1 | 2012 | 113 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2017 | 640 | 0.030 |
Why?
| Thiazoles | 1 | 2012 | 130 | 0.030 |
Why?
| Aorta, Thoracic | 1 | 2013 | 163 | 0.030 |
Why?
| Heart Diseases | 1 | 2014 | 288 | 0.030 |
Why?
| Fibrosis | 1 | 2012 | 188 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 266 | 0.030 |
Why?
| Eosinophils | 1 | 2012 | 192 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 372 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2016 | 1367 | 0.030 |
Why?
| Carrier Proteins | 1 | 2015 | 662 | 0.030 |
Why?
| Retreatment | 1 | 2011 | 103 | 0.030 |
Why?
| Myocardial Contraction | 1 | 2012 | 240 | 0.030 |
Why?
| African Americans | 1 | 2019 | 1076 | 0.030 |
Why?
| Body Mass Index | 1 | 2014 | 740 | 0.030 |
Why?
| Up-Regulation | 1 | 2013 | 688 | 0.030 |
Why?
| Rats, Mutant Strains | 1 | 2010 | 23 | 0.030 |
Why?
| Connexins | 1 | 2012 | 196 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2013 | 1015 | 0.030 |
Why?
| SOXD Transcription Factors | 1 | 2010 | 1 | 0.030 |
Why?
| Cell Membrane | 1 | 2014 | 666 | 0.030 |
Why?
| Biomimetics | 1 | 2010 | 25 | 0.030 |
Why?
| Butadienes | 1 | 2010 | 33 | 0.030 |
Why?
| Losartan | 1 | 2010 | 45 | 0.030 |
Why?
| SOX9 Transcription Factor | 1 | 2010 | 22 | 0.030 |
Why?
| Microarray Analysis | 1 | 2010 | 93 | 0.030 |
Why?
| Renin | 1 | 2010 | 76 | 0.030 |
Why?
| Aggrecans | 1 | 2010 | 42 | 0.030 |
Why?
| Chondrocytes | 1 | 2010 | 59 | 0.020 |
Why?
| Chromatin | 1 | 2012 | 330 | 0.020 |
Why?
| Heterochromatin | 1 | 2009 | 21 | 0.020 |
Why?
| Hypertrophy | 1 | 2009 | 62 | 0.020 |
Why?
| Enhancer Elements, Genetic | 1 | 2012 | 260 | 0.020 |
Why?
| Nuclear Envelope | 1 | 2009 | 35 | 0.020 |
Why?
| Vitamins | 1 | 2010 | 71 | 0.020 |
Why?
| Diet | 1 | 2013 | 427 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2010 | 232 | 0.020 |
Why?
| Nitriles | 1 | 2010 | 140 | 0.020 |
Why?
| Stress Fibers | 1 | 2009 | 22 | 0.020 |
Why?
| Catalase | 1 | 2009 | 48 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2010 | 152 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2010 | 305 | 0.020 |
Why?
| Laminin | 1 | 2009 | 81 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 318 | 0.020 |
Why?
| Binding Sites | 1 | 2012 | 1083 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2012 | 918 | 0.020 |
Why?
| Adenoviridae | 1 | 2010 | 345 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2019 | 1525 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1278 | 0.020 |
Why?
| Cytoskeletal Proteins | 1 | 2009 | 219 | 0.020 |
Why?
| Interleukin-6 | 1 | 2009 | 226 | 0.020 |
Why?
| DNA Primers | 1 | 2009 | 542 | 0.020 |
Why?
| Blotting, Western | 1 | 2010 | 777 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1161 | 0.020 |
Why?
| Antioxidants | 1 | 2009 | 213 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 869 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2010 | 626 | 0.020 |
Why?
| Indiana | 1 | 2006 | 12 | 0.020 |
Why?
| Base Sequence | 1 | 2009 | 2323 | 0.020 |
Why?
| Antihypertensive Agents | 1 | 2010 | 567 | 0.020 |
Why?
| Skin Diseases | 1 | 2006 | 160 | 0.020 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2006 | 253 | 0.020 |
Why?
| Surgical Instruments | 1 | 2004 | 56 | 0.020 |
Why?
| Apoptosis | 1 | 2010 | 1646 | 0.020 |
Why?
| Carcinoma, Renal Cell | 1 | 2006 | 397 | 0.010 |
Why?
| Kidney Neoplasms | 1 | 2006 | 584 | 0.010 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|